Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
In this double-blind, cross-over, placebo-controlled, randomized study, possible extraintestinal effects of miglitol, an absorbable alpha-glucosidase inhibitor, were investigated. Sixteen healthy male volunteers underwent two 75 g oral glucose tolerance tests with concomitant administration of miglitol or placebo. Peak and post-peak areas under the curve values for blood glucose, serum insulin and serum C-peptide after miglitol were not different from those found after placebo. The post-peak AUC-ratio (AUC (peak, 180 min) on miglitol/AUC (peak, 180 min) on placebo) was for glucose 1.15 (CI 0.94-1.40, P = 0.16), for insulin 1.12 (CI 0.95-1.33, P = 0.17) and for C-peptide 0.98 (CI 0.81-1.18, P = 0.82). It is concluded that miglitol exerts no clinically relevant extraintestinal effects on glucose control.
Sels
J P
JP
Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
Nauta
J J
JJ
Menheere
P P
PP
Wolffenbuttel
B H
BH
Nieuwenhuijzen Kruseman
A C
AC
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives; D000328:Adult; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D005944:Glucosamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D050112:Imino Pyranoses; D007328:Insulin / Q000097:blood; D007421:Intestine, Small / Q000378:metabolism*; D008297:Male; D010919:Placebos
D001786:Blood Glucose; D002096:C-Peptide; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D050112:Imino Pyranoses; D007328:Insulin; D010919:Placebos; C045621:miglitol; D017485:1-Deoxynojirimycin; D005944:Glucosamine